Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20261819 TM471-1 Multiple Sclerosis, Relapsing-Remitting Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261819 clinical trial report covering TM471-1, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20261623 Coenzyme I Ovarian Insufficiency Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
CTR20261623 clinical trial report covering Coenzyme I, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07586826 Tretinoin Ovarian Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586826 clinical trial report covering Tretinoin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07586813 Tretinoin Thrombocytopenia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586813 clinical trial report covering Tretinoin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07587840 tanCART-19/22 cells Follicular Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07587840 clinical trial report covering tanCART-19/22 cells, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07587801 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Hemodialysis complication Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07587801 clinical trial report covering Influenza Vaccine, Adjuvanted(Seqirus GmbH), Phase 2, endpoints, sponsor, geography, readout timing and development
Latest Hotspot
8 min read
NCT07586865 Gletimbetasin Anterior Wall Myocardial Infarction Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586865 clinical trial report covering Gletimbetasin, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07587775 Abaloparatide Osteoporotic Fractures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07587775 clinical trial report covering Abaloparatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
![NCT07586046 Yttrium [90Y] chloride Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook](https://synapse-static.patsnap.com/strapi-static/Blog_cover_13_1a4cebe3b5.jpg)
Latest Hotspot
8 min read
NCT07586046 Yttrium [90Y] chloride Hepatocellular Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586046 clinical trial report covering Yttrium [90Y] chloride, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07586124 Pucotenlimab Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586124 clinical trial report covering Pucotenlimab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07586202 Amivantamab-VMJM EGFR-mutated non-small Cell Lung Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07586202 clinical trial report covering Amivantamab-VMJM, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07589439 Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals) Asthma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
24 July 2026
NCT07589439 clinical trial report covering Recombinant anti-IL-4Rα nanobody(Shanghai Novamab Biopharmaceuticals), Phase 2, endpoints, sponsor, geography, read